Physician profile
Lance P Horner
NPI 1952842205
$4,674.72
in general payments reported to CMS, 2019-2025
13 companies · $569 in 2025
The $569 reported for 2025 was more than what a typical Colon & Rectal Surgery provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $162 · 2022: $1,081 · 2023: $1,324 · 2024: $1,538 · 2025: $569.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,818 · Travel and Lodging: $604 · Gift: $8.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,818.11 |
| Travel and Lodging | $604.06 |
| Gift | $8.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $879.90 | 2023-2024 | Da Vinci Surgical System |
| Abbvie INC. | $869.15 | 2023-2025 | |
| Medtronic, INC. | $714.62 | 2023 | Interstim |
| Allergan, INC. | $696.74 | 2021-2022 | |
| Tela Bio, INC. | $471.42 | 2023-2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Thd America, INC. | $292.20 | 2022 | |
| Innovation Technologies INC | $152.50 | 2022 | |
| Ethicon US, LLC | $131.67 | 2024 | Echelon; Endopath |
| Takeda Pharmaceuticals U.S.A., INC. | $111.02 | 2024 | Gattex |
| Axogen | $103.03 | 2024 | Axoguard Nerve Connector, Avance Nerve Graft, Axoguard Ha+ Nerve Protector |
| Integra Lifesciences Corporation | $102.37 | 2021 | |
| Boston Scientific Corporation | $90.10 | 2023 | Resolution 360 Clip |
| Vertex Pharmaceuticals Incorporated | $60.00 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lance Horner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.